Bal Pharma's Q2 FY 2025-26 Quarterly Results
- 21 Nov 2025
Result Summary
- Bal Pharma Ltd reported a 12.8% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Sep (Q2 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 2.2%.
- Its expenses for the quarter were up by 12.1% QoQ and 3.2% YoY.
- The net profit increased 242.9% QoQ and decreased 30.8% YoY.
- The earnings per share (EPS) of Bal Pharma Ltd stood at 0.45 during Q2 FY 2025-26.
Financial Statments for Q2 FY 2025-26
Total Income | 75.14 | 66.59 | 73.49 | 12.8% | 2.2% |
Total Expenses | 74.42 | 66.38 | 72.13 | 12.1% | 3.2% |
Profit Before Tax | 0.72 | 0.21 | 1.36 | 242.9% | -47.1% |
Tax | 0.00 | 0.00 | 0.32 | - | -100.0% |
Profit After Tax | 0.72 | 0.21 | 1.04 | 242.9% | -30.8% |
Earnings Per Share | 0.45 | 0.13 | 0.65 | 246.2% | -30.8% |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
Bal Pharma Ltd is a pharmaceutical company engaged in the manufacturing and marketing of pharmaceutical formulations and active pharmaceutical ingredients (APIs). The company primarily operates in the healthcare and pharmaceutical industry, offering a range of products that cater to both domestic and international markets. The company's portfolio includes a variety of therapeutic segments such as anti-diabetic, anti-hypertensive, anti-bacterial, and anti-inflammatory products. As of the data available, there is no specific information on recent major developments within the company or industry that could impact its financial performance. It is important to note that any recent strategic initiatives or external factors affecting the industry are not provided in the current dataset.
Revenue
In the second quarter of fiscal year 2026 (Q2FY26), Bal Pharma Ltd reported a total income of ₹75.14 crores. This represents an increase of 12.8% quarter-over-quarter (QoQ) from ₹66.59 crores in the first quarter of fiscal year 2026 (Q1FY26). When compared year-over-year (YoY) with the second quarter of fiscal year 2025 (Q2FY25), where the total income was ₹73.49 crores, there is a modest growth of 2.2%. This growth in revenue over both the quarterly and yearly periods may be attributed to various factors such as increased sales volume, pricing adjustments, or expansion into new markets, although specific details are not provided in the data.
Profitability
Bal Pharma Ltd's profitability metrics for Q2FY26 reveal a Profit Before Tax (PBT) of ₹0.72 crores, which is a significant QoQ increase of 242.9% from ₹0.21 crores in Q1FY26. However, when compared to the PBT of ₹1.36 crores in Q2FY25, there is a YoY decline of 47.1%. The Profit After Tax (PAT) for Q2FY26 stands at ₹0.72 crores, reflecting the same QoQ growth of 242.9% from Q1FY26, but a YoY decrease of 30.8% from ₹1.04 crores in Q2FY25. The Earnings Per Share (EPS) also follows this pattern, with a QoQ rise to ₹0.45 from ₹0.13, yet a YoY drop from ₹0.65. Notably, the tax expense for Q2FY26 is reported as ₹0.00 crores, compared to ₹0.32 crores in Q2FY25, highlighting a 100% decrease in tax liability.
Operating Metrics
The total expenses for Bal Pharma Ltd in Q2FY26 were reported at ₹74.42 crores, marking a 12.1% increase QoQ from ₹66.38 crores in Q1FY26. On a YoY basis, these expenses rose by 3.2% from ₹72.13 crores in Q2FY25. The substantial increase in expenses QoQ could be attributed to various operational factors, which are not detailed in the dataset. The company's operating efficiency, as reflected in the profit margins before and after tax, shows variability with significant improvements QoQ but declines YoY. The absence of tax expenses in the current quarter may have impacted post-tax profitability metrics. The data highlights the fluctuations in fiscal performance over different time periods without detailing specific operational causes.